Expert Interview
Evaluating the potential of new therapies in development for Waldenstrom macroglobulinemia with a focus on Iopofosine I 131 (CLR131) SM radiotherapeutic from Cellectar and mavorixafor from X4 Pharma
Ticker(s): CLRB, XFORInstitution: Mass General
- Clinical investigator and attending physician at Massachusetts General Hospital Cancer Center.
- Treats patients with plasma cell dyscrasias with a particular focus on multiple myeloma as well as Waldenstrom’s macroglobulinemia and other IgM-related disorders.
- Research interests include global health, studying immune dysregulation, and developing more effective oncologic treatment strategies, which minimize toxicity and infectious complications.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
